EUVIMEDEUVIMED entdecken
ValidierungsstudieOpen Access · CC BY-NC-ND 4.0

Adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia undergoing allogeneic hematopoietic stem cell transplantation and tyrosine kinase inhibitors: development and validation of a clinical prediction model based on cytogenetics, IKZF1 deletions and minimal residual disease

Jing Zheng, Yuping Zhou, Yanmin Zhao, Yi Luo, Jian Yu, Xiaoyu Lai, Jinuo Wang, Yishan Ye, Lizhen Liu, Huarui Fu, Luxin Yang, Yibo Wu und 10 weitere

Annals of Hematology · 2025

DOI: 10.1007/s00277-025-06202-7 ↗

Kurz gefasst

Validierungsstudie in der Zeitschrift Annals of Hematology, 2025. Verfasst von Jing Zheng und 21 weiteren Autor:innen. Beteiligte Einrichtung: Bone Marrow Transplantation Center, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, 310000, China. Hauptthemen laut MEDLINE: Hematopoietic Stem Cell Transplantation, Ikaros Transcription Factor, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Protein Kinase Inhibitors. Die Arbeit nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The aim of this study was to develop and validate a nomogram predicting progression-free survival (PFS) for adult patients with positive acute lymphoblastic leukemia(Ph + ALL) who have undergone allogeneic hematopoietic stem cell transplantation(allo-HSCT) and tyrosine kinase inhibitor(TKI) treatment. Data were retrospectively collected from 176 adult patients diagnosed with Ph + ALL and treated with allo-HSCT and TKIs at The First Affiliated Hospital, Zhejiang University School of Medicine, between January 2015 and May 2023. 70% of the patients were randomly assigned to the training group(n = 124) and 30% of the patients were assigned to the validation group(n = 52). Univariate Cox regression analysis and Akaike Information Criterion(AIC) were utilized to identify significant predictive factors, leading to the development of a nomogram designed to forecast the probability of PFS at 6, 9, and 12 months post-transplantation. The final nomogram incorporated three key variables: presence of complex additional cytogenetic abnormalities (ACAs), minimal residual disease (MRD) status prior to allo-HSCT, and IKZF1 gene deletions. The calibration curves showed excellent consistency between the nomogram prediction and actual observation for 6-, 9- and 12-month PFS in the training set and validation set. The C-index of the training set was 0.726(95%CI: 0.635-0.816), which was no significantly different from the validation set(C-index = 0.774, 95%CI: 0.674-0.875, P > 0.05). This study may provide a simple and efficient prediction model for patients with Ph + ALL undergoing allo-HSCT and TKIs, which can accurately predict PFS subsequent to transplantation. This tool could potentially aid clinicians in decision-making processes and improve patient outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hematopoietic Stem Cell TransplantationIkaros Transcription FactorPrecursor Cell Lymphoblastic Leukemia-LymphomaProtein Kinase InhibitorsNomogramsPhiladelphia ChromosomeGene DeletionHumansAdultMaleFemaleNeoplasm, ResidualMiddle AgedRetrospective StudiesTransplantation, HomologousYoung AdultAdolescentAgedAllograftsTyrosine Kinase Inhibitors

Stichwörter der Autor:innen

CytogeneticIKZF1 deletionMinimal residual diseaseNomogramPositive acute lymphoblastic leukemiaProgression-free survival

Substanzen

Ikaros Transcription FactorProtein Kinase InhibitorsIKZF1 protein, humanTyrosine Kinase Inhibitors

Autor:innen und Institutionen

  • Bone Marrow Transplantation Center, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, 310000, China.
  • Departments of Hematology, The First College of Clinical Medical Science, China Three Gorges University, Yichang Central People's Hospital, Yichang, 443000, China.
  • Bone Marrow Transplantation Center, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, 310000, China. huanghe@zju.edu.cn.
  • Department of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430000, China. lee937@126.com.
  • Bone Marrow Transplantation Center, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, 310000, China. shijimin@zju.edu.cn.

Zitieren

APA

Zheng, J., Zhou, Y., Zhao, Y., Luo, Y., Yu, J., Lai, X., Wang, J., Ye, Y., Liu, L., Fu, H., Yang, L., Wu, Y., Sun, J., Zheng, W., He, J., Zhao, Y., Wu, W., Cai, Z., Wei, G., …, & Shi, J. (2025). Adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia undergoing allogeneic hematopoietic stem cell transplantation and tyrosine kinase inhibitors: development and validation of a clinical prediction model based on cytogenetics, IKZF1 deletions and minimal residual disease. Annals of Hematology. https://doi.org/10.1007/s00277-025-06202-7

Vancouver

Zheng J, Zhou Y, Zhao Y, Luo Y, Yu J, Lai X, et al. Adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia undergoing allogeneic hematopoietic stem cell transplantation and tyrosine kinase inhibitors: development and validation of a clinical prediction model based on cytogenetics, IKZF1 deletions and minimal residual disease. Annals of Hematology. 2025. doi:10.1007/s00277-025-06202-7

BibTeX
@article{Zheng2025,
  author = {Zheng, Jing and Zhou, Yuping and Zhao, Yanmin and Luo, Yi and Yu, Jian and Lai, Xiaoyu and Wang, Jinuo and Ye, Yishan and Liu, Lizhen and Fu, Huarui and Yang, Luxin and Wu, Yibo and Sun, Jie and Zheng, Weiyan and He, Jingsong and Zhao, Yi and Wu, Wenjun and Cai, Zhen and Wei, Guoqing and Huang, He and Li, Weiming and Shi, Jimin},
  title = {Adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia undergoing allogeneic hematopoietic stem cell transplantation and tyrosine kinase inhibitors: development and validation of a clinical prediction model based on cytogenetics, IKZF1 deletions and minimal residual disease},
  journal = {Annals of Hematology},
  year = {2025},
  doi = {10.1007/s00277-025-06202-7}
}
Kostenlos starten →